RAPH (Raphael Pharmaceutical) Total Stockholders Equity: $-1.66 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RAPH Raphael Pharmaceutical Inc RAPH
37 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Total Stockholders Equity?

Raphael Pharmaceutical RAPH 37 Total Stockholders Equity is $-1.66 Mil as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Raphael Pharmaceutical's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-1.66 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Raphael Pharmaceutical's Book Value per Share for the quarter that ended in Mar. 2026 was $-0.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Raphael Pharmaceutical's Debt-to-Equity for the quarter that ended in Mar. 2026 was -0.02.

Raphael Pharmaceutical  (OTCPK:RAPH) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Raphael Pharmaceutical's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-1.662-0)/20.176
=-0.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Raphael Pharmaceutical's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.037 + 0) / -1.662
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Total Stockholders Equity Related Terms

Raphael Pharmaceutical Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Total Stockholders Equity Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 0.13 0.11 0.11 -0.74 -1.43

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -1.05 -1.26 -1.43 -1.66
RAPH
37GF Score
Raphael Pharmaceutical Inc RAPH
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-1.66 Mil mean?
Raphael Pharmaceutical (RAPH) has a Total Stockholders Equity of $-1.66 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Total Stockholders Equity too high?
Raphael Pharmaceutical's current Total Stockholders Equity is $-1.66 Mil. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Total Stockholders Equity compare to TXMD and AYTU?
Raphael Pharmaceutical's Total Stockholders Equity of $-1.66 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Total Stockholders Equity is $-1.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Total Stockholders Equity of $-1.66 Mil. The current Total Stockholders Equity is $-1.66 Mil. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Total Stockholders Equity is $-1.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score

Get the complete analysis for RAPH

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price